Teva Launches First Generic Version of Sandostatin® LAR Depot
01 Oct 2024 //
GLOBENEWSWIRE
Shuangcheng `s Generic Octreotide Acetate Receives Approval In U.S
02 May 2024 //
FDA
Gland`s Generic Octreotide Acetate Receives Approval in the U.S.
13 Jun 2023 //
FDA
Amryt Pharmaceuticals`s Mycapssa (octreotide) Receives Approval in Europe
22 Dec 2022 //
EMA
Enforcement Report - Week of November 16, 2022
16 Nov 2022 //
FDA
Mylan Recalls Lot of Octreotide Acetate Injection, 500 mcg/mL
26 Oct 2022 //
BLOOMBERGLAW
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly
16 Sep 2022 //
GLOBENEWSWIRE
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (
07 Sep 2022 //
GLOBENEWSWIRE
Amryt Receives ODD from FDA for Mycapssa for Carcinoid Syndrome
14 Jul 2022 //
GLOBENEWSWIRE
Amryt to Present Data from PIII Trials Open Label Extension of Mycapssa
08 Jun 2022 //
GLOBENEWSWIRE
Teva`s troubled plant seen to create injectable drug shortages
24 May 2022 //
FIERCEPHARMA
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa
13 Apr 2022 //
GLOBENEWSWIRE
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa
11 Jan 2022 //
GLOBENEWSWIRE
Results from Amyrt’s Phase 3 Trial of Mycapssa Published in The Lancet
04 Jan 2022 //
TRIALSITENEWS
Enforcement Report - Week of August 25, 2021
25 Aug 2021 //
FDA
A biotech with a yen for pricey rare disease drugs — and bargain
05 May 2021 //
ENDPTS
Chiasma Announces Positive Topline Results from the MPOWERED™ Ph3 MYCAPSSA®
18 Nov 2020 //
PRESS RELEASE
Chiasma’s Octreotide Capsules Could Be Answer to Acromegaly Treatment Burdens
18 Sep 2020 //
BIOSPACE
Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®
31 Aug 2020 //
GLOBENEWSWIRE
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Study
27 Jul 2020 //
GLOBENEWSWIRE
Camargo client Chiasma receives FDA approval for first only oral somatostatin
02 Jul 2020 //
PRNEWSWIRE
Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules
26 Jun 2020 //
GLOBENEWSWIRE
Novartis tips complex manufacturing to insulate Sandostatin from generics
04 Feb 2020 //
IN-PHARMATECHNOLOGIST
Sandostatin LAR can steer clear of generics in 2020: Novartis
04 Feb 2020 //
FIERCE PHARMA
CBL Approved by EMA & FDA
05 Dec 2019 //
PRESS RELEASE
Novartis offloads lagging endocrine drugs to Recordati for $390M
16 Jul 2019 //
FIERCE PHARMA
USV Pharms` Generic Octreotide Acetate Receives Approval in US
27 Dec 2018 //
FDA
USV North America`s Generic Octreotide Acetate Receives Approval in US
12 Sep 2018 //
FDA
Novartis NET app gets an App Store launch boost
23 Jul 2018 //
FIERCE PHARMA
Glide raises £3.2m for solid dose injector programme
02 Feb 2017 //
PHARMATIMES
Generics set to undercut blockbusters from Merck, Novartis and Bristol-Myers
18 Jan 2017 //
FIERCE PHARMA
The FDA`s Promo Police Slap Four More Pharmas in Year-End Enforcement Spree
30 Dec 2016 //
FIERCE PHARMA
US FDA Enforcement Report- 1/June/2016
31 May 2016 //
FDA
Government restores customs duty exemption on three drugs
17 Feb 2016 //
ECONOMIC TIMES
Glide Announce Successful Proof-of-Concept With Novel Exenatide Formulation
05 Jan 2016 //
PR NEWS WIRE
Acromegaly treatment: Oral Octreotide could capture market from late 2015
18 Nov 2015 //
BIOSPECTRUM INDIA
With Roche Out the Door, Chiasma is Raising $56M to Go it Alone
02 Jan 2015 //
FIERCE BIOTECH